Caffeine
Viewing r1 — Apr 25, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Caffeine (1,3,7-trimethylxanthine) is a naturally-occurring stimulant of the xanthine class. It is the most widely consumed psychoactive substance on Earth. It works by blocking adenosine — a brain chemical that signals fatigue — keeping arousal and attention systems switched on.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Caffeine was first isolated from coffee beans in 1819 by the German chemist Friedlieb Ferdinand Runge.[3] Hermann Emil Fischer completed its total synthesis in 1895, work that contributed to his Nobel Prize in Chemistry.[3] Today, over 80% of Western adults consume it daily — its psychoactive nature rarely acknowledged by its users.[1]
Subjective effects include wakefulness, sharper focus, mild mood lift, and increased motivation. The experience is primarily restorative — caffeine lifts performance degraded by fatigue back toward a rested baseline, rather than enhancing cognition above it.[4] Anxiety, restlessness, and disrupted sleep are the characteristic downsides, with individual response shaped in part by genetic variation in adenosine receptors.[5][6]
Caffeine produces low-to-moderate physical dependence, with withdrawal causing headache, fatigue, and low mood.[7] A fatal dose requires far more than beverages can deliver,[8][9] but concentrated powder products have caused fatalities at doses impossible to reach through drinks alone.[10] Caffeine is among the most thoroughly studied psychoactive substances in pharmacology, with over a century of clinical and epidemiological data.
History[edit]
Discovery
Caffeine was first isolated from coffee beans in 1819 by the German chemist Friedlieb Ferdinand Runge — a discovery prompted by Johann Wolfgang von Goethe, who provided the beans.[3] French chemists independently confirmed the isolation in 1821. Hermann Emil Fischer completed the first total synthesis in 1895, contributing to his Nobel Prize in Chemistry.[3]
Clinical and scientific significance
In 1999, a comprehensive review by Fredholm et al. established adenosine receptor blockade as the primary driver of caffeine's effects on the brain.[1] This mechanism also explained a long-established medical use: caffeine citrate had been treating breathing pauses in premature newborns for decades, a practice confirmed and expanded by the 2006 CAP trial.[11]
Present-day status
Caffeine is now consumed worldwide in coffee, tea, cocoa, energy drinks, and soft drinks. Over 80% of adults in Western societies consume it in pharmacologically active doses daily.[1] It is the most widely used psychoactive substance on Earth — and unlike nearly any other, its drug status goes largely unrecognized by the people using it.
The name "caffeine" derives from the French caféine, coined during the independent French isolations of 1821. Historical synonyms reflect its botanical ubiquity: theine (from tea) and guaranine (from guarana) were once treated as distinct substances before chemical analysis proved them identical to caffeine.[12] Caffeine occurs naturally in over 60 plant species, where it functions as a natural insecticide — a defense mechanism that humans co-opted into the world's most popular drug.
Chemistry[edit]
Structure
Caffeine (1,3,7-trimethylxanthine) belongs to the methylxanthine family — a group of purine-derived alkaloids.[12][13] Its molecular formula is C₈H₁₀N₄O₂. It dissolves in both water and fat, which allows near-complete absorption from the gut and ready passage into the brain.[14][13]
Structural relatives
When the liver breaks caffeine down, it produces three active compounds: paraxanthine (~84% of metabolic output), theobromine (~12%), and theophylline (~4%).[14] All three retain pharmacological activity. Caffeine also occurs naturally in over 60 plant species — including coffee, tea, cocoa, and guarana.[12]
Pharmacology[edit]
Mechanism of action
Caffeine blocks adenosine receptors in the brain.[15][2] Adenosine accumulates during wakefulness and progressively slows neural activity — the brain's built-in signal that sleep is needed. Blocking it removes that brake, freeing up arousal and dopamine signaling.[1]
Downstream effects on neurotransmitters
Blocking adenosine in the striatum enhances dopamine signaling, producing mild mood lift and locomotor activation.[1] Blocking it in the cortex and hippocampus releases glutamate from tonic suppression, sharpening attention and memory.[16]
Pharmacokinetics
Caffeine absorbs near-completely from the gut and reaches peak blood levels within 30–60 minutes.[14] The liver enzyme CYP1A2 handles ~95% of its metabolism, converting it to three active products: paraxanthine (~84%), theobromine (~12%), and theophylline (~4%).[14][17] The half-life averages 3–5 hours — but doubles with oral contraceptives,[14] triples during pregnancy,[14] shrinks by 65% in smokers,[18][14] and extends to 65–100 hours in newborns who lack CYP1A2 entirely.[19]
Neuroscience[edit]
Where it acts
In the striatum, caffeine blocks adenosine receptors that normally dampen dopamine signaling.[2] Removing that suppression enhances dopamine transmission, producing mild mood elevation and locomotor activation.[1] In the prefrontal cortex and hippocampus, blocking a different adenosine receptor releases glutamate from tonic suppression, sharpening attention and memory consolidation.[16]
Cognitive normalization and neuroprotection
Caffeine functions as a cognitive normalizer — restoring performance lost to fatigue or sleep deprivation rather than enhancing cognition above a rested baseline.[4] This is why caffeine "improves" attention primarily in tired people.
Habitual caffeine use is consistently associated with lower rates of Parkinson's disease[20][21] and possibly Alzheimer's disease,[22] though Mendelian randomization studies have not confirmed a causal relationship.[23]
- Paraxanthine's role: Caffeine's primary breakdown product, paraxanthine, is a more potent adenosine blocker with a different side-effect profile.[14] Its independent contribution to the caffeine experience is unquantified.
- Incomplete wakefulness tolerance: tolerance develops to caffeine's stimulant and cardiovascular effects but not fully to its wakefulness promotion.[24] Why these diverge remains unresolved.
- Genetic variation: Variants in the ADORA2A gene influence how anxiogenic caffeine is for a given person,[5] but the full scope — including effects on tolerance and withdrawal severity — is poorly characterized.
Subjective Effects[edit]
Caffeine's experience is fundamentally restorative. When fatigue has dimmed focus or flattened mood, caffeine lifts both back toward a rested state. The experience reads as clarity and momentum — thoughts sharpen, the drag of tiredness recedes. Whether that constitutes enhancement depends entirely on how depleted the person was to begin with.[4]
Compared to amphetamine and other stimulants, caffeine is considerably softer — weaker euphoria, gentler onset, no sharp crash. It removes adenosine's brake on arousal rather than forcing the accelerator. Individual response varies substantially: the same dose that produces calm focus in one person can trigger restless anxiety in another, depending on genetic makeup.[5]
Effect Grid
At common doses (100–300 mg oral, equivalent to 1–3 cups of brewed coffee), the full stimulant profile emerges. Wakefulness and alertness are pronounced. Attention and vigilance are consistently improved, with reduced reaction time and enhanced sustained focus. Thought acceleration is evident, and motivation for task completion increases. Mood is mildly elevated, with increased sociability and verbal fluency.
Physically, increased heart rate, mild blood pressure elevation, and diuresis are expected. Mild tremor may be noticeable in caffeine-naïve individuals. Appetite suppression is common. Sleep onset will be delayed if consumed within 6 hours of bedtime.
At the upper end of this range (200–300 mg), some individuals — particularly those with ADORA2A polymorphisms or anxiety disorders — may experience restlessness, irritability, or mild anxiety rather than focused alertness.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Taste suppression · Touch enhancement · Light sensitivity · Tinnitus · Auditory hallucinations · External hallucinations
Auditory hallucinations · External hallucinations
Appetite suppression · Insomnia · Respiratory stimulation · Physical fatigue · Restlessness · Headache · Heart rate perception changes · Trembling · Nausea · Dehydration sensation · Muscle tension · Pain suppression · Motor control enhancement · Dizziness · Excessive sweating · Bruxism · Diarrhea · Pupil dilation · Temperature dysregulation · Yawning · Sexual arousal enhancement · Tactile euphoria · Motor control impairment · Vomiting · Seizure threshold reduction
Physical fatigue · Restlessness · Headache · Heart rate perception changes · Trembling · Nausea · Dehydration sensation · Muscle tension · Pain suppression · Motor control enhancement · Dizziness · Excessive sweating · Bruxism · Diarrhea · Pupil dilation · Yawning · Sexual arousal enhancement · Tactile euphoria · Motor control impairment · Vomiting · Seizure threshold reduction
Motivation enhancement · Analysis enhancement · Information processing enhancement · Memory enhancement · Cognitive euphoria · Thought organization · Motivation suppression · Cognitive flexibility · Pattern recognition enhancement · Language enhancement · Cognitive dysphoria · Confusion · Thought disorganization · Thought loops
Cognitive euphoria · Thought organization · Motivation suppression · Cognitive flexibility · Pattern recognition enhancement · Language enhancement · Cognitive dysphoria · Confusion · Thought disorganization · Thought loops
Anhedonia · Dysphoria
Ego inflation
Timeline
First perceptible effects emerge 10–30 minutes after ingestion — a subtle sense of increasing alertness and reduced fatigue. Effects may appear faster on an empty stomach.
Alertness builds steadily as plasma levels rise toward Cmax. Mental clarity sharpens, motivation increases, and physical energy becomes noticeable.
Maximum stimulation coincides with peak plasma concentration (Tmax ~30–60 min). Alertness, focus, and mood elevation are at their strongest. At higher doses, anxiety and restlessness may dominate.
Sustained but gradually diminishing stimulation as plasma levels decline through the elimination half-life. Productive wakefulness continues, though peak sharpness fades.
Effects taper to baseline over 1–2 hours. Fatigue may return, sometimes more noticeably than before dosing due to adenosine rebound. Mild headache possible in regular users as levels drop.
Residual subclinical stimulation persists for 2–4 hours after subjective effects resolve, with potential for sleep disruption if consumed in the afternoon or evening.
⚠ Do not drive or operate machinery if experiencing fatigue rebound or if caffeine was used to compensate for significant sleep deprivation.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- theophylline · theobromine · paraxanthine
Toxicity
Acute toxicity
The estimated lethal dose is approximately 150–200 mg/kg — roughly 10.5–14 g for a 70 kg adult, or about 80–100 cups of brewed coffee.[8][9] Poisoning progresses in stages depending on dose:
- Mild-moderate (>500–1,000 mg): Palpitations, rapid heart rate, tremor, anxiety, nausea, headache
- Severe (>1,000 mg): Heart rhythm disturbances, metabolic acidosis, low potassium, seizures, muscle breakdown
- Life-threatening (>5 g): Cardiac arrest, cardiovascular collapse, respiratory failure, death
For severe caffeine overdose: activated charcoal if within 1–2 hours of ingestion; IV beta-blockers (esmolol) for heart rhythm disturbances; benzodiazepines for seizures; dialysis for extreme overdose; correct low potassium and metabolic acidosis.[8]
Cardiovascular effects
Caffeine raises blood pressure and heart rate by triggering catecholamine release.[9] It also constricts blood vessels in the brain[25] — a property exploited in headache medications.
At high doses, particularly from energy drinks, caffeine can trigger dangerous heart rhythms through cardiac calcium overload.[26] Sudden cardiac arrest in young adults has been documented in association with energy drink consumption.[10]
Concentrated caffeine products
In 2018, the FDA effectively banned direct-to-consumer sale of pure powdered caffeine after multiple overdose deaths.[27] A single teaspoon of pure caffeine powder contains approximately 3,200 mg — eight times the recommended daily maximum — making accurate dosing without laboratory equipment essentially impossible.
Pregnancy
A meta-analysis of 60 publications found dose-dependent risks per 100 mg daily caffeine increment[28]:
- +14% risk of miscarriage (95% CI: 10–19%)
- +19% risk of stillbirth (95% CI: 5–35%)
- +7% risk of low birth weight (95% CI: 1–12%)
- +10% risk of small-for-gestational-age infants (95% CI: 6–14%)
No threshold below which these associations disappear has been identified. Current guidelines recommend ≤200 mg/day during pregnancy.[29]
Psychological risks
Caffeine produces dose-dependent anxiety[5][6]:
- Low doses (50–150 mg): Mild alerting, possible mood lift
- Moderate-to-high doses (200–500 mg): Anxiety, irritability, restlessness
- High doses (>500 mg): Palpitations, marked anxiety, possible panic attacks
- Very high doses: Rare psychotic or manic symptoms have been reported[5]
People with panic disorder are especially vulnerable — caffeine challenge reliably triggers panic attacks in this population.[6] Genetic variation in the ADORA2A gene further modulates the anxiety threshold.[5] Caffeine withdrawal can also closely mimic psychiatric disorders — anxiety, depression, and cognitive impairment — making it a documented source of clinical misdiagnosis.[7]
Tolerance and dependence
Tolerance develops to many of caffeine's effects with regular use, particularly locomotor stimulation.[1] The mechanism involves upregulation of adenosine receptors in the striatum.[16] Tolerance to wakefulness-promoting effects is incomplete — caffeine remains wake-promoting even in chronic users, though the effect is blunted.[24]
Physical and psychological dependence are both low-to-moderate. Caffeine Withdrawal is a fully diagnosable DSM-5 condition; Caffeine Use Disorder is designated for further study.[7]
Withdrawal syndrome (DSM-5 recognized)[7]:
- Onset: 12–24 hours after last dose
- Peak: 20–51 hours
- Duration: 2–9 days
- Symptoms: Headache (most common), fatigue, low mood, difficulty concentrating, irritability, flu-like symptoms
- Mechanism: Withdrawal headache results from blood vessel dilation in the brain when caffeine's constricting effect wears off[25]
Drug interactions
CYP1A2 metabolic interactions
A single liver enzyme — CYP1A2 — handles ~95% of caffeine metabolism, so any drug that blocks it dramatically increases caffeine exposure. Fluvoxamine is the most significant: standard doses extend caffeine's half-life from ~5 hours to 31 hours,[30][31] and even low doses cause substantial inhibition.[32] Patients starting fluvoxamine who maintain their usual caffeine intake risk caffeine toxicity; other relevant inhibitors include ciprofloxacin, enoxacin, and oral contraceptives.[14]
Smoking accelerates caffeine clearance by 40–65%.[18][14] Quitting smoking therefore raises effective caffeine levels, potentially triggering toxicity symptoms in heavy coffee drinkers.
Stimulant combinations
Caffeine dramatically amplifies MDMA toxicity — increasing overheating, rapid heart rate, cardiovascular stress, and long-term nerve damage.[33] Similar toxicity enhancement applies to cocaine, amphetamine, and ephedrine.[33]
Caffeine and alcohol
Caffeine partially masks the feeling of intoxication but does not reduce blood alcohol levels or actual impairment.[34] People mixing caffeine and alcohol — particularly energy drink cocktails — may dangerously overestimate their ability to drive or function safely.
Adenosine receptor drugs
Caffeine directly opposes the effects of intravenous adenosine used in cardiac emergencies, and of adenosine-based cardiac imaging agents like regadenoson and dipyridamole. Caffeine must be avoided for 12–24 hours before cardiac perfusion imaging.
Contraindications
Panic disorder and anxiety disorders: Caffeine reliably triggers panic attacks in patients with panic disorder and worsens generalized anxiety.[6] Individuals with these conditions should minimize or avoid caffeine.
Heart rhythm disorders: High-dose caffeine can trigger dangerous heart rhythms through cardiac calcium overload.[10][26] Patients with pre-existing rhythm disorders or long QT syndrome should limit intake.
Pregnancy: Dose-dependent risks for miscarriage, stillbirth, and low birth weight, with no identified safe threshold below 200 mg/day.[28]
CYP1A2 inhibitor co-administration: Patients on fluvoxamine, ciprofloxacin, or other potent CYP1A2 inhibitors face dramatically elevated caffeine exposure and should reduce intake proportionally.[30]
Newborns and infants: Absent CYP1A2 at birth results in caffeine half-lives of 65–100 hours.[19] Caffeine use in neonates is therapeutic and medically supervised only.
High blood pressure: Caffeine acutely raises blood pressure via catecholamine release; individuals with uncontrolled hypertension should monitor intake.
Harm Reduction[edit]
Forms & Identification
Most people encounter caffeine in labeled commercial products — coffee, tea, energy drinks, soft drinks, and OTC tablets — where identity is not in question.
The risk shifts with bulk caffeine powder and capsules purchased online. These are extremely potent, and accurate dosing without a milligram-precision scale is essentially impossible. A kitchen spoon can hold a dangerous amount.
Energy drinks vary widely in caffeine content — from 80 to 300+ mg per container — and this is not always prominently labeled. Multiple cans in quick succession, especially alongside alcohol, can push total intake into dangerous territory.
Guidelines
- Know the dose: a standard cup of brewed coffee contains approximately 80–100 mg of caffeine; espresso ~63 mg per shot; energy drinks vary from 80 to 300+ mg per container
- Start lower when caffeine-naïve or returning after a break — 50–100 mg provides a meaningful effect without established tolerance
- Avoid caffeine within 6–8 hours of intended sleep time
- If consistent caffeine-induced anxiety appears, reduce the dose rather than pushing through — ADORA2A genetic variants make some individuals genuinely more vulnerable
- Never use bulk caffeine powder without a milligram-precision scale — a single teaspoon contains approximately 3,200 mg
- Advisory daily limits: ≤400 mg for adults, ≤200 mg during pregnancy
Set & Setting
Context shapes caffeine's effects more than most users recognize. The same dose that produces focused productivity during a calm morning can generate restless anxiety under stress or time pressure.
Those who notice consistent anxiety as a caffeine effect should treat it as a biological signal. Genetic variation in adenosine receptors makes some individuals genuinely more prone to caffeine-induced anxiety — this is not a personal failing.
Sleep timing matters more than most users realize. Caffeine's 3–5 hour half-life means an afternoon dose retains significant stimulant activity at bedtime. Poor sleep increases fatigue, which drives more caffeine use, which further disrupts sleep — a self-reinforcing cycle.
Aftercare & integration. After acute overconsumption (>500 mg), prioritize hydration, electrolyte replacement, and sleep once the stimulant effects subside. The body recovers fastest when metabolic demands are reduced. Avoid additional stimulants for at least 24 hours.
For those reducing or quitting habitual caffeine use, withdrawal management is the primary concern. Taper gradually — reducing by 25% every few days — rather than stopping abruptly. Expect headache, fatigue, and low mood peaking at 20–51 hours after the last dose, resolving within 2–9 days. Over-the-counter pain suppression can manage withdrawal headache; adequate hydration and extra sleep support recovery.
Recovery & Support
Caffeine dependence is real but generally mild compared to other substance dependencies. The DSM-5 recognizes Caffeine Withdrawal as a diagnosable condition and designates Caffeine Use disorder for further study. Most people who wish to quit or reduce can do so independently through gradual tapering over 1–2 weeks.
For individuals who find caffeine use genuinely difficult to control — particularly those consuming >500 mg daily or experiencing significant anxiety, sleep disruption, or repeated failed quit attempts — structured support may help. Cognitive behavioral approaches used for other substance dependencies apply to caffeine. A healthcare provider can help rule out underlying conditions (anxiety disorders, sleep disorders) that may be driving excessive use.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable but safe: jitteriness, mild nausea, rapid heartbeat that resolves within an hour. Needs immediate help: chest pain, seizure, severe confusion, loss of consciousness, uncontrollable vomiting, or a heart rate that feels irregular rather than simply fast.
Immediate steps:
- 1. Call emergency services if the person has seized, lost consciousness, or reports chest pain
- 2. Do not induce vomiting
- 3. If conscious and ingestion was within the last 1–2 hours, emergency services may administer activated charcoal
- 4. Place an unconscious person in the recovery position
- 5. Monitor breathing and heart rate while waiting for help
What to tell the dispatcher: State the substance (caffeine), the estimated amount ingested, the time of ingestion, and current symptoms. Note whether the source was pills, powder, or energy drinks. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Caffeine is not a controlled or scheduled substance in any major jurisdiction — regulatory attention focuses on concentration limits in products rather than access restrictions.[29][27]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not scheduled; GRAS food additive | GRAS at ≤200 ppm in cola-type beverages. OTC stimulant under FDA monograph. FDA recommends ≤400 mg/day. Bulk powdered caffeine effectively banned for consumer sale (2018)[27] |
| European Union | Not controlled | EFSA limits: ≤400 mg/day adults, ≤200 mg single dose, ≤200 mg/day pregnant women. No safe limit established for children/adolescents[29] |
| United Kingdom | Not controlled | Food Standards Agency aligns with EFSA limits (≤400 mg/day adults) |
| Canada | Not scheduled | Health Canada: ≤400 mg/day adults, ≤300 mg/day pregnant women |
| Australia | Not scheduled | TGA regulates caffeine-containing medicines; FSANZ sets food standards |
| International sport (WADA) | Monitoring Program | Removed from Prohibited List in 2004; remains on the Monitoring Program |
Legal status varies by jurisdiction and changes over time. This information is provided for general reference only and is not legal advice.
references
- [1]
- [2] ^abcFredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. — Pharmacological Reviews doi:10.1124/pr.110.003285
- [3]
- [4] ^abcCunha RA, Agostinho PM (2010) Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. — Journal of Alzheimer's Disease doi:10.3233/jad-2010-1408
- [5]
- [6] ^abcdKlevebrant L, Frick A (2022) Effects of caffeine on anxiety and panic attacks in patients with panic disorder: A systematic review and meta-analysis. — General Hospital Psychiatry doi:10.1016/j.genhosppsych.2021.11.005